Literature DB >> 25597822

HIV-1 induces in vivo platelet activation by enhancing platelet NOX2 activity.

Daniele Pastori1, Antonella Esposito2, Roberto Carnevale3, Simona Bartimoccia1, Marta Novo1, Alessandra Fantauzzi2, Francesco Di Campli2, Pasquale Pignatelli4, Francesco Violi1, Ivano Mezzaroma2.   

Abstract

OBJECTIVES: HIV-1 patients show increased platelet activation, but the mechanisms involved are not completely clarified. We speculated that HIV-1 might induce in vivo platelet activation by enhancing platelet NOX2-related oxidative stress.
METHODS: We measured soluble CD40 Ligand (sCD40L), a systemic marker of platelet activation, in 36 HIV-1 patients under effective combined antiretroviral therapy (cART) and in 10 naïve HIV-1 subjects. As control, 20 healthy subjects (HS) were included. Platelet oxidative stress was measured by platelet NOX2-derived peptide (sNOX2-dp), p47(phox) translocation to platelet membrane and platelet prostaglandin F2α (8-iso-PGF2α).
RESULTS: sCD40L was increased both in HIV-1 naïve and cART patients compared to HS (p < 0.001). Platelet sNOX2-dp and 8-iso-PGF2α were significantly higher in HIV-1 naïve subjects compared to those on cART and to HS, and both were mutually correlated (R = 0.734, p < 0.001). A stepwise multivariable linear regression analysis showed that platelet sNOX2-dp (β: 0.803, p < 0.001), HIV-1 infection (β: 0.146, p = 0.014) and age (β: 0.166, p = 0.001) were independently associated to sCD40L levels.
CONCLUSIONS: HIV-1 infection is associated with increased platelet oxidative stress, which was related to the activation of NOX2. The independent association between platelet NOX2 activation and plasma levels of sCD40L suggest that in vivo platelet activation may be dependent upon platelet oxidative stress.
Copyright © 2015 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HIV-1; Isoprostanes; NOX; Platelet activation

Mesh:

Substances:

Year:  2015        PMID: 25597822     DOI: 10.1016/j.jinf.2015.01.005

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  Serum NOX2 as a new biomarker candidate for HBV-related disorders.

Authors:  Yuan Xiong; Yuanyuan Ye; Pu Li; Yahui Xiong; Jinju Mao; Yong Huang; Weixian Chen; Bo Wang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy.

Authors:  Daniele Pastori; Ivano Mezzaroma; Pasquale Pignatelli; Francesco Violi; Gregory Y H Lip
Journal:  Br J Clin Pharmacol       Date:  2019-01-11       Impact factor: 4.335

3.  Platelet-HIV: interactions and their implications.

Authors:  Sidney W Whiteheart
Journal:  Platelets       Date:  2022-01-04       Impact factor: 3.862

Review 4.  Platelets in HIV: A Guardian of Host Defence or Transient Reservoir of the Virus?

Authors:  Etheresia Pretorius
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

Review 5.  Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets.

Authors:  Morris Madzime; Theresa M Rossouw; Annette J Theron; Ronald Anderson; Helen C Steel
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

Review 6.  Platelets as Key Factors in Inflammation: Focus on CD40L/CD40.

Authors:  Fabrice Cognasse; Anne Claire Duchez; Estelle Audoux; Theo Ebermeyer; Charles Antoine Arthaud; Amelie Prier; Marie Ange Eyraud; Patrick Mismetti; Olivier Garraud; Laurent Bertoletti; Hind Hamzeh-Cognasse
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

7.  Platelet activation in adult HIV-infected patients on antiretroviral therapy: a systematic review and meta-analysis.

Authors:  Bongani B Nkambule; Vuyolwethu Mxinwa; Zibusiso Mkandla; Tinashe Mutize; Kabelo Mokgalaboni; Tawanda M Nyambuya; Phiwayinkosi V Dludla
Journal:  BMC Med       Date:  2020-11-18       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.